Abstract Whether the high incidence of venous thromboembolism (VTE) in the elderly can be attributed to cancer is not well studied. We assessed the impact of cancer on risk of VTE in young, middle-aged and elderly. 26,094 subjects without a history of cancer or VTE were recruited from the Tromsø study. Incident cancer (n = 2,290) and VTE (n = 531) were recorded from baseline (1994)(1995) through December 31st, 2009. Cox regression with cancer as time-varying exposure was used to calculate hazard ratios with 95 % confidence intervals (CI). Overt cancer was associated with a fivefold (95 %CI 4.3, 6.7) increased risk of VTE, with an age-dependent gradient from 26-fold (95 %CI 12.1, 56.5) increased in the young, ninefold (95 % CI 6.6, 12.7) increased in the middle-aged, and threefold (95 % CI 2.5, 4.5) increased risk in the elderly. The population attributable risks were 14, 27 and 18 %, respectively. Conclusion: The relative risk of VTE by cancer were higher in young compared to elderly subjects, but the proportion of VTEs in the population due to cancer did not differ much across age groups.
Introduction
Deep vein thrombosis (DVT) and pulmonary embolism (PE), together referred to as venous thromboembolism (VTE), are frequent and life threatening complications of malignancy [1, 2] . An increased incidence of VTE in patients with cancer has been unambiguously demonstrated [3] , and the risk is shown to be particularly increased during the first few months after diagnosis as well as in the presence of distant metastases [4] . Overall, cancer is responsible for up to 25 % of all incident VTE cases [2, 5, 6] . The aetiology of cancer associated VTE is heterogeneous, and pathogenic mechanisms include tumour induced hypercoagulability, vascular injury caused by the tumour, chemotherapy or surgery, long term central venous catheters, venous stasis among bedridden patients, and tumourdependent compression of the venous circulation [7] . In subjects with cancer, a VTE event is associated with more frequent and prolonged hospital stays [8] , more severe treatment complications [9] , increased risk of recurrence [9, 10] and shortened life-expectancy compared to cancer patients without VTE [11, 12] .
The incidence of VTE is strongly age-dependent, and varies from 1 per 100,000 per year in young subjects to 1 % per year in the elderly [2, 13] . Likewise, malignant disease is substantially more prevalent at higher ages [14] . Thus, it is reasonable to assume that cancer contributes to the increased VTE incidence observed in the elderly population. However, despite the well-known association between cancer and VTE, limited data exist on the strength of the association at different ages. A few studies have indicated that cancer may be less of a risk factor in old age than at younger ages [15, 16] . In a small sub-study of the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA) study, the relative risk of VTE was substantially higher in those younger than 70 compared to the elderly [15] . Moreover, a Danish population-based registry study with hospitalization for VTE as primary outcome, showed that the relative risk of cancer associated VTE was highest in the younger age groups [16] . Similar findings were recently reported in a study using United Kingdom linked databases [17] .
Several statistical measures can be used to express the importance of a causal risk factor in development of disease, and both the frequency of the exposure and the strength of the association need to be considered. The attributable risk (AR %) represents the share of events among the exposed that can be explained by the exposure, whereas the population attributable risks (PAR %) represent the share of events in a population that can be explained by a specific exposure.
The increased risk of VTE observed in the elderly is not well understood. Therefore, the aim of the present study was to investigate whether the increased risk of VTE at high age could be attributed to cancer. We used a general population cohort to assess future age-specific incidence rates (IRs) and relative risks of VTE in patients with occult and overt cancer. AR % and PAR % were calculated to illustrate the impact of cancer on VTE in the young, middle-aged and elderly.
Methods

Study population and baseline measurements
Participants were recruited from the fourth survey of the Tromsø study (conducted in 1994-1995), a single-centre, population-based cohort study. All inhabitants of Tromsø municipality [24 years were invited and 27,157 (77 % of the eligible population) participated. The study was approved by the regional committee of research ethics, and all participants gave their informed written consent to participate. Subjects who did not approve of medical research (n = 201) and subjects no longer registered as inhabitants of Tromsø municipality (n = 44), were excluded from the study. Furthermore, subjects with a known medical history of VTE (n = 53) or a history of cancer (n = 763) were excluded. Thus, the baseline population included 26,094 subjects with no prior cancer or VTE.
Baseline information was obtained by physical examination and self-administered questionnaires. Body height and weight were measured with the participants wearing light clothing and no shoes. The body mass index (BMI) was calculated as the weight in kilograms divided by the square of the height in meters (kg/m 2 ). Information about physical activity, smoking habits, diabetes and previous cardiovascular diseases (angina, myocardial infarction and stroke) were obtained from self-administered questionnaires. The questions for physical activity were ''How many times per week do you usually perform light or hard physical activity'' (none, less than once per week, one-two times per week or three or more times per week for the two respective questions). The questions used to assess smoking status were ''Do you smoke cigarettes, cigars or pipe daily'' (yes or no for each tobacco). The number of daily cigarettes, years of smoking and time since smoking cessation were also collected.
Cancer assessment
Information on incident cancer during follow-up, e.g. date of cancer diagnosis and location of malignancy (International Classification of Disease, Revision 7 (ICD-7) codes 140-205), excluding non-melanoma skin cancer (ICD-7 191.0-191.9), was obtained from the Cancer Registry of Norway. In a recent evaluation of the data quality, completeness of reporting was estimated to 98.8 %, whereas organ specific morphology had 94 % accuracy [18] .
Venous thromboembolism assessment
Potential first life time diagnoses of VTE were identified by searching the hospital discharge diagnosis registry, the autopsy registry and the radiology registry at the University Hospital of North Norway, as previously described [19] . The University Hospital of North Norway is the only hospital serving the municipality of Tromsø, and all relevant diagnostic procedures and specialized care are exclusively performed by this hospital. The hospital discharge diagnosis registry included both outpatient clinic visits and hospitalizations. A VTE-event was recorded when all four of the following criteria were fulfilled; (1) the diagnosis was objectively verified (compression ultrasonography, venography, spiral computed tomography, perfusion-ventilation scan, pulmonary angiography or autopsy); (2) the physician had made a diagnosis of DVT or PE in the patient's medical journal; (3) signs and symptoms consistent with DVT or PE were present; and (4) treatment with anticoagulants (heparin, warfarin), thrombolytic therapy or vascular surgery was required. From the autopsy registry VTE-events were included when PE was the noted cause of death, or marked as a significant condition on the death certificate.
From the patient's medical journal, possible provoking factors other than cancer were registered. Provoking factors were: recent surgery or trauma within the previous 8 weeks, acute medical conditions (acute myocardial infarction, ischemic stroke or major infectious disease), marked immobilization (bed rest for [3 days, wheelchair use, or long-distance travel exceeding 4 h within the last 14 days prior to the event) or other provoking factors specifically described by a physician in the medical record (e.g. intravascular catheter).
Study design
All subjects were included in the study during 1994-95, and followed to the date of a VTE event, migration, death, or end of the study period (Dec 31st, 2009), whichever occurred first. Person-time of cancer exposure were calculated in three categories; no cancer exposure, occult cancer exposure (the 1 year period before cancer was diagnosed), and overt cancer exposure. Thus, subjects who developed cancer during follow-up (n = 2,290) contributed with non-exposed person-time from their baseline inclusion date until the date 1 year prior to their cancer diagnosis; then they contributed with 1 year of occult cancer exposure time; and overt cancer exposure time was measured from the date of manifest cancer diagnosis (Fig. 1) . The dataset was divided into three age groups (\50, 50-69, C70 years), and the person-times (with and without cancer exposure) each subject spent in each age group were calculated. In total, the 26,094 individuals contributed to 43,287 observational periods. The main study outcome was incident VTE (n = 531), and subjects who died (n = 3,895) or migrated (n = 3,429) during follow-up were censored from the date of death or migration.
Statistical analyses
Statistical analyses were carried out using STATA version 12 (Stata corporation, College station, Texas, USA). All analyses were performed for the total cohort, as well as in the three age groups; \ 50, 50-69 and C70 years. Crude IRs with corresponding 95 % confidence intervals (95 % CI) for VTE were calculated for occult cancer-exposure, overt cancer exposure and non-cancer exposure. Attributable risk (AR %), the share of events among the exposed subjects that can be explained by the exposure, was calculated from IRs of VTE in the cancer (I e ) and non-cancer (I o ) population ( IeÀIo Ie Á 100%). Population attributable risk fraction (PAR %) was calculated using the IRs of VTE in the general population (I p ) and in the non-cancer (I o ) population (PAR% ¼ IpÀIo Ip Á 100%). AR % and PAR % were calculated by total cancer exposure (i.e. overt ? occult cancer).
Cox proportional hazards regression models were used to calculate cause-specific hazard ratios (HR) for VTE for exposure to total-, occult-and overt cancer. In the Coxmodel, cancer was entered as a time dependent variable, age was used as timescale, and analyses were stratified by age groups and adjusted for sex. To address potential confounding, BMI, daily smoking (yes/no), physical activity, self-reported cardiovascular disease and diabetes at baseline were included in a multivariable model. Residual confounding by smoking quantity was investigated by inclusion of pack-years for current smokers in an additional multivariable model. The proportional hazard assumption was verified by evaluating the parallelism between the curves of the log-log survivor function.
In order to formally test that the effect of age on risk of VTE was independent of cancer, the HR of VTE per decade increase in age adjusted for cancer was estimated by Cox-regression.
Competing risk of death
Hypothetically, death may prevent the observation of a future potential VTE during the follow-up period, and it has been suggested that the cause specific HRs may overestimate the risk of cancer-related VTE [20] . Since the Person A: contributed with non-exposed person-time from inclusion until 1-year prior to cancer diagnosis; then 1-year occult cancer time followed, and overt cancer exposure was calculated from diagnosis until VTE event. Person B: non-cancer exposed through the whole study period. Person C: occult cancer related VTE Cancer and VTE 279 overall risk of mortality, and potentially cancer-related mortality, was expected to be different across age groups (i.e. higher in the elderly), we also calculated subhazard ratios taking competing risk of death into account by using the model described by Fine and Gray [21] .
Results
Baseline characteristics by age groups are shown in Table 1 . The majority of study participants were\50 years (63.0 %), whereas 9.5 % were C70 years at inclusion. As expected, the proportion of women was higher among the elderly. BMI, the proportion of subjects with diabetes and self-reported CVD increased across higher age groups, whereas the proportion of daily smokers and the frequency of physical activity decreased (Table 1) . Among the 26,094 study participants included at baseline, 2,290 (8.8 %) developed cancer during a median follow-up of 14.8 years. Cancer was more common among the elderly (C70 years at time of cancer diagnosis) with an IR of 22 per 1,000 person-years, whereas the corresponding rates among the middle-aged and young was 8 per 1,000 and 1.8 per 1,000, respectively. In the young, breast cancer was the most common cancer site in women (37 %), whereas colorectal cancer and nervous system tumours were common cancers for both sexes (Table 2 ). In the middle aged and elderly, prostate cancer was common in men (33 and 26 % respectively), and breast cancer was frequent in women (30 and 13 % respectively). Colorectaland lung cancer were frequent sites in middle-aged (14 and 11 %, respectively) and elderly patients (19 and 16 %, respectively). Advanced cancer stage was more common among elderly subjects (21 %) compared to the young and middle-aged (13 and 17 %, respectively) ( Table 2) . A total of 531 VTE events occurred throughout the study period (Table 3) , of which 27 (5.1 %) in subjects with occult cancer, and 111 (21 %) in subjects with overt cancer (Table 4) . Immobilization was the most common provoking factor in cancer-related VTE (23 %), followed by surgery and acute medical conditions (15 %), whereas among the non-cancer VTEs, surgery and immobilization were equally common (16 and 19 %, respectively) and acute medical conditions were described in 15 % of the events. The proportion of subjects with PE was slightly higher among non-cancer related VTEs (41 vs. 36 %) (Table 3) .
Overall, the crude IR of VTE in the population was 1.6 per 1,000 person-years. Among the cancer free the IR was 1.2 per 1,000, whereas among the occult and overt cancer exposed the IRs were 12.2 and 13.0 per 1,000 person-years, respectively ( Table 4 ). The IRs of VTE increased across age groups in both exposed and The Tromsø study [1994] [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] For breast, prostate and gynecological cancers sex-specific percentages are presented * Esophagus, stomach and small intestine unexposed subjects. In the non-cancer exposed, IRs of VTE in the youngest through highest age groups were 0.3, 1.2 and 4.4 events per 1,000 person-years, respectively. In the overt cancer population, corresponding IRs of VTE were 9.2, 11.9 and 15.1 per 1,000 person-years. Among the young subjects with cancer, 96 % of the VTE events could be explained by cancer, while the corresponding proportions were 91 % among middle aged and 70 % among the elderly cancer patients. The overall population attributable risk (PAR %) by cancer (overt ? occult) was 24 %. In young subjects, 14 % of the VTE events occurred due to cancer, whereas the corresponding proportions were 27 % among middleaged and 18 % in the elderly (Table 4) . The overall cause specific HRs for VTE by occult cancer and overt cancer were 5.2 (95 % CI 3.5, 7.8) and 5.4 (95 % CI 4.3, 6.7), respectively (Table 5 ) compared with non-cancer. The relative risk of VTE by overt cancer was highest among the young and decreased across age groups. Similar results were found for occult cancer, though we had limited power to calculate the relative risk among the young. Young subjects with overt cancer had a 26-fold increased risk of VTE (95 % CI 12.1, 56.5), whereas middle-aged and elderly had a ninefold (95 % CI 6.6, 12.7) and threefold (95 % CI 2.5, 4.5) increased risk, respectively. The hazard ratios were not altered after adjustment for BMI, daily smoking, physical activity, self-reported cardiovascular disease and diabetes. The multivariable model adjusted for packyears instead of daily smoking provided similar risk estimates (data not shown). When death was taken into account in the competing risk model, the overall risk estimate for VTE by overt cancer was attenuated from fivefold to threefold. However, the subhazard ratio indicated that the risk was still 21-fold higher in the young, whereas the corresponding estimates for middleaged and elderly were close to sevenfold and twofold, respectively.
Finally, in the total population, the risk of VTE per 10 year increment in age (HR 1.9, 95 % CI 1.8, 2.0) was only slightly attenuated by adjustment for cancer (HR 1.8, 95 % CI 1.7, 1.9).
Discussion
We found that the overall risk of VTE in cancer patients was more than five-fold increased. Despite a higher proportion of advanced cancers in the elderly, we observed a significant age gradient, from a 26-fold increased relative risk in the youngest to a threefold increased relative risk in the highest age group compared to subjects without cancer. Crude IRs in the cancer and non-cancer cohorts were 13.0 and 1.2 per 1,000 person-years, respectively. The AR of VTE due to cancer was highest among the young and declined with increasing age from 96 % in the young to 70 % in the elderly. However, the proportion of VTE events that could have been saved if cancer was completely eliminated from the population did not differ much in the young and elderly (14 vs. 18 %, respectively) despite the substantially higher (tenfold) IR of cancer in the elderly. Thus, our findings suggest that the high incidence of VTE by advancing age cannot be explained by the concomitant high prevalence of cancer in the elderly. Our finding of an overall fivefold increased risk of VTE by cancer is in agreement with previous cohort [16, 17] and case-control studies [4, 22] reporting a 5-7 fold higher risk of VTE in cancer patients. Age-specific IRs and relative risks were reported in a previous Danish registry study [16] that had linked a cohort of 57,600 cancer patients with a cohort of 287,000 controls selected from the general population. Since the primary outcome of the Danish study was hospitalization for VTE, the IRs and risk estimates were not directly comparable to our study which included both hospitalized and outpatient treated VTEs. Moreover, when a subgroup of the VTE diagnoses in the registry were validated, the codes for hospitalized VTE cases had a low positive predictive value (PPV 75 %), particularly when VTE was a secondary discharge diagnosis (PPV 67 %) [23] . However, similar to our findings, the Danish study reported increasing IRs of VTE across older age groups among cancer patients, while the relative risks of VTE by cancer was highest among the young. A recent linkage of UK databases [17] with 83,000 cancer patients and 580,000 controls reported a HR of 4.7 for all cancers combined, and higher IR in subjects [60 years, compared to those \60 years. For certain high risk sites (e.g. pancreas, lung, mesothelioma), the IRs were higher in young subjects. Similar to our findings the UK linked databases found an overall IR of 14 per 1,000 person-years, and a meta-analysis of 38 papers on cohorts with cancer patients (of which 7 were of average risk patients) reported an IR of 13 per 1,000 person-years [24] .
VTE is a multicausal disease [25] among which age is one of the most consistent and strongest risk factors. Along with an age-dependent increase in the incidence of cancer, a substantial increase in PAR of cancer for VTE by age would be expected. Previously, few attempts have been made to estimate the PAR of cancer for VTE in the young and elderly [15, 26] . Engbers and colleagues estimated the PAR to be 15 % in the younger population and 35 % in the elderly, based on an assumption that the relative risk of VTE was constant across age groups in cancer patients [26] . In our study, we were able to calculate PAR based on actual IRs of cancer and VTE using a general population cohort followed closely for a maximum of 14 years. As previous studies have indicated [15, 16] , our data confirmed that on a relative scale cancer was associated with significantly lower risk of VTE in the elderly than in the young. Thus, the proportion of events that could be attributed to cancer increased only slightly by increasing age. In coherence with these findings, the HR for VTE per 10 year increment in age remained virtually similar after adjustment for cancer in the total population.
The absolute risk difference between cancer and noncancer was similar in the three age groups and ranged from 7 to 11 cases per 1,000 persons per year. Since cancer is substantially more common in elderly subjects, it could be reasonable to assume that cancer would lead to a higher proportion of VTE events among the elderly at a population level. However, in our study cancer was responsible for 27 % of the VTE cases among middle aged subjects, and only 18 % of the VTEs in patients aged 70 years or older. Thus, clearly, cancer is not the main contributor to the increased incidence of VTE by advancing age. A number of comorbidities and VTE risk factors become more frequent with increasing age. Ischemic heart disease, stroke, severe infections and hospitalizations all accumulate in the elderly. Other risk factors like age-related changes in vessel walls and valves, or distributed flow due to less muscle strength and tone, may also contribute to increased VTE risk. Further on, the share of VTE events with inherited thrombophilia decline with increasing age [27] , suggesting that acquired risk factors become gradually more important at higher ages. Consequently, presence of other risk factors for VTE may dilute the relative importance of cancer as a risk factor in older patients. In a previous study [26] , the AR for VTE in cancer patients was estimated to be 86 % in both young and elderly patients with cancer. However, we observed a gradient in AR from 96 % in young cancer patients to 70 % among elderly cancer patients. This observation supports the notion that accumulated co-morbidities and other VTE risk factors diluted the impact of cancer on VTE risk in the elderly. From another perspective, the risk associated with cancer may be more pronounced in young and middle-aged subjects due to a more adverse course of the malignant disease and/or more aggressive cancer therapy in these patients.
With regard to aetiology, the cause specific HRs are the most important in assessment of cancer-related VTE risk. However, it has been claimed that mortality should be considered a competing risk factor when studying the occurrence of VTE events in a cancer population [20] , since the cause specific HRs may overestimate the risk of cancer-related VTE. When competing risk by death was taken into account in our study, the risk estimates of VTE by overt cancer were attenuated in all age groups, and as expected, most attenuated among the elderly due to higher mortality rate in this age group.
A clear advantage of our study is the high completeness and validity of the VTE events. Furthermore, the high participation rate among people recruited from a general population, and the prospective study design with long follow-up time contribute to a high quality. As cancer is a relatively rare exposure in the general population, a limitation of our study is the size of the exposed population, which prohibits the use of smaller age ranges in the calculations and sub-group analysis of specific cancer sites. Since cancer is already a well-established risk factor for VTE, diagnostic bias may be present due to a lower threshold for performing the diagnostic procedures of VTE in subjects with manifest malignancy. Moreover, some of the apparently cancer free subjects who died during followup may have had occult cancer. Thus, fatal venous thrombotic events in patients with occult cancer could be misclassified as non-cancer exposed events, and therefore our risk estimates by occult cancer may be slightly underestimated. Finally, information about cancer treatment was not available in our study. Since the frequency of different treatment modalities may vary according to age, treatment represents a potential confounder in the comparison of the age-groups that could not be taken into account.
In conclusion, the relative risk of VTE by cancer was higher in young subjects, and the PAR declined considerably from middle-aged to elderly subjects. Thus, our findings suggest that cancer is not a major contributor to the increased risk of VTE by advancing age, and that VTE would continue to be a disease substantially more common in the elderly if cancer did not exist in the population.
